Menu
PeproMene Bio Appoints Bruce A. Beutler, MD, to the Scientific Advisory Board
Irvine, CA, October 2, 2017 – PeproMene Bio, Inc., a development stage biotechnology company focused on BAFF-R target CAR-T cell to develop novel cancer and immuno-oncology therapies, today announced the appointment of Bruce A. Beutler as its Scientific Advisor. Dr. Beutler is an honorary awardee of Novel Prize in Physiology or Medicine in 2011. He is best known for his pioneering molecular and genetic studies of inflammation and innate immunity. He was the first to isolate mouse tumor necrosis factor-alpha (TNF), and to demonstrate the inflammatory potential of this cytokine, proving its important role in endotoxin-induced shock.

Bryan Hong Woo Kim, Chief Executive Officer at PeproMene Bio, said, “We are pleased to welcome Bruce Beutler to the Company, as we are building our advisory board. Bruce’s excellent track record and his amazing experience will be valuable to the Company, and we look forward to his contributions toward our future success.”

Dr. Beutler is currently a Regental professor and director of Center for the Genetics of Host Defense, UT Southwestern Medical Center. He also currently serves as a Raymond and Ellen Willie Distinguished Chair in Cancer research, in honor of Laverne and Raymond Willie, Sr. Other than that, for more than 30 years, he had served as a professor in many science field.

About PeproMene Bio

PeproMene Bio, Inc. is a virtual, privately funded biotech company located Irvine, CA. We are developing novel immune-oncology therapies such as BAFF-R CAR-T therapy based on the novel antibodies. The BAFF-R CAR-T therapy program which was discovered and developed from Dr. Larry Kwak’s lab at MD Anderson and City of Hope was successfully licensed in from City of Hope, Duarte CA, in April 2017. Currently the further development is on going at City of Hope for its IND enabling study. We will continue to license-in and explore more of novel immuno-oncology programs via our network. For more information about the Company, please visit www.pepromenebio.com.

Contact

Steve Lee: 949-564-4085, steve@pepromenebio.com
List